Orexo to present at Rodman & Renshaw 6th Annual Global Healthcare Conference

Uppsala, Sweden – Orexo AB today announces that the company will present at the Rodman & Renshaw 6th Annual Global Healthcare Conference on May 17, 2010. The conference is held on May 16-18 at the Grosvenor House Hotel in London, UK and attracts investors from the international financial community. The full conference schedule can be found on www.rodm.com/conferences. The slides from Orexo´s presentation will subsequently be available on www.orexo.com. For further information, contact: Torbjörn Bjerke, President and CEO, Orexo AB Tel: +46 (0)708-66 19 90 E-mail: torbjorn.bjerke@orexo.com Claes Wenthzel, Executive Vice President and CFO, Orexo AB Tel: +46 (0)708-62 01 22 E-mail: claes.wenthzel@orexo.com About Orexo Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four products on the market as well as a broad project portfolio in late stages of development. Sales and marketing are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Abstral for the treatment of break through cancer pain is today Orexo’s most important product. Abstral was launched in major European countries in 2009 and is in registration phase in the USA, Canada and Japan. Orexo has 108 employees, and has its head office located in Uppsala, Sweden. More information can be found at www.orexo.com. Note: This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was provided for public release on May 7, 2010 at 17:00 CET.

Tags: